Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics (GALT), has demonstrated a clear selling bias in his recent insider transactions, with no open-market purchases recorded in the past year. Since November 2025, Callicutt has executed 11 sales totaling $998,050.11, including three notable dispositions in early January 2026: a $74,695.11 sale on January 6, a $100,298.19 transaction on January 5, and a $58,394.28 sale on January 2. These followed earlier sales in November 2025, including a $174,866.30 transaction on November 18 and a $118,830.52 sale on November 17. The pattern shows consistent divestment, with multiple sales clustered around mid-November 2025 and early January 2026. While some transactions involved modest amounts like $10,094.56 and $11,321.36, others exceeded $100,000, indicating material reductions in his GALT position. The absence of any recent buys contrasts with his historical acquisition of $191,804.91 in company stock, suggesting a shift toward portfolio rebalancing or liquidity needs. All activity has been concentrated in GALT shares, with no diversification into other securities. The transactions occurred through both direct sales (code S) and automatic dispositions (code M), with the latter typically representing tax withholding or option exercises.
AI-assisted summary